Velcade (bortezomib)
Velcade
was approved by FDA in 2003 as a new and effective medicine in treatment of
Multiple Myeloma. Velcade is a third line treatment for Myeloma, i.e. it
is used in individuals who have failed to respond to two other types of
chemotherapy combinations. Velcade blocks the activity of proteasomes which are
enzymes that play a role in regulating cell function and growth. . This blockade
may lead to death of Myeloma cells.
Side
effects:
Following side effects are attributed to this drug:
It is imperative that a patient relay any side effects or
problems to her/his medical oncologist.
